,This study document brings together 147 carefully worded exam questions drawn from UTA NURS
5333 test 1 Exam (2026) UPDATE Verified Questions And Answers With 100% Correct Answers
graded A+ Guaranteed Success!!, with the strongest emphasis placed on Analyze pharmacokinetic
and pharmacodynamic principles to predict drug response and adverse effects in complex patient
scenarios, Apply current evidence-based guidelines to select, monitor, and adjust pharmacologic
therapy for common and high-risk conditions, Integrate pathophysiologic mechanisms with clinical
data to formulate safe and patient-centered prescriptive decisions. Every item follows the wording
style and level of reasoning you meet in the real paper, and each one is paired with a clear
rationale so the correct choice is never a guess. Work through the set at your own pace, mark the
questions that slow you down, then come back to them until the reasoning feels automatic.
Learners who revise this way walk into the exam room recognising the pattern behind the
questions instead of meeting them for the first time. Keep going - steady, honest practice is what
turns a difficult paper into a comfortable pass.
Q1 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
A patient with heart failure and reduced ejection fraction (HFrEF) is initiated on
sacubitril/valsartan. Which mechanism best explains why this agent must not be
co-administered with an ACE inhibitor within 36 hours?
A. Additive bradykinin accumulation from dual neprilysin and ACE inhibition increases
angioedema risk. CORRECT
B. Sacubitril inhibits ACE, leading to unopposed angiotensin II effects and hypertension.
C. Valsartan blocks AT1 receptors, causing reflex tachycardia that negates sacubitril's benefit.
D. Combined therapy reduces renal perfusion by inhibiting prostaglandin synthesis.
RATIONALE: Sacubitril inhibits neprilysin, which degrades bradykinin; concurrent ACE inhibition
also raises bradykinin, markedly increasing angioedema risk. Option B is false because sacubitril
does not inhibit ACE. Option C is incorrect because reflex tachycardia is not the primary concern
and valsartan does not negate sacubitril's benefit. Option D is unrelated; prostaglandin synthesis
is not the mechanism.
Page 2
,Q2 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
Which pathophysiologic alteration best explains the development of hyperkalemia
in a patient with metabolic acidosis and insulin deficiency?
A. Increased renal potassium excretion due to aldosterone excess
B. Extracellular shift of potassium via H+/K+ exchange and reduced cellular uptake CORRECT
C. Enhanced sodium-potassium ATPase activity driving potassium intracellularly
D. Decreased gastrointestinal potassium absorption
RATIONALE: In acidosis, hydrogen ions move into cells in exchange for potassium moving out;
insulin deficiency further impairs cellular potassium uptake, causing hyperkalemia. Option A is
wrong because aldosterone excess would lower potassium. Option C would lower serum
potassium. Option D does not cause hyperkalemia; reduced GI absorption would lower
potassium.
Q3 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
A patient on warfarin for atrial fibrillation is prescribed
trimethoprim-sulfamethoxazole for a urinary tract infection. Which
pharmacokinetic interaction is most likely to occur?
A. Induction of CYP2C9, decreasing INR and thromboembolic risk
B. Inhibition of CYP2C9, increasing INR and bleeding risk CORRECT
C. Increased renal clearance of warfarin, reducing its effect
D. Displacement from albumin without altering free drug concentration
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, the enzyme metabolizing
S-warfarin, leading to increased INR and bleeding risk. Option A is incorrect because induction
would decrease INR. Option C is wrong; renal clearance is not the primary mechanism. Option D
is incorrect because displacement alone does not usually cause a sustained increase in free drug
unless metabolism is also inhibited.
Page 3
, Q4 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
A patient with type 2 diabetes and chronic kidney disease (eGFR 32 mL/min/1.73
m²) is on metformin. Which action is most appropriate according to current FDA
labeling and clinical guidelines?
A. Continue metformin at current dose with routine monitoring.
B. Discontinue metformin and initiate an SGLT2 inhibitor. CORRECT
C. Reduce metformin dose by 50% and recheck eGFR in 3 months.
D. Switch to a sulfonylurea due to renal safety.
RATIONALE: Metformin is contraindicated when eGFR is below 30 mL/min/1.73 m² and should
not be initiated; at eGFR 32, many guidelines recommend discontinuation or dose reduction, but
an SGLT2 inhibitor is preferred for renal and cardiovascular protection. Option A is unsafe.
Option C is not aligned with current recommendations. Option D is less optimal because
sulfonylureas risk hypoglycemia in CKD.
Q5 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
Which statement best describes the concept of 'therapeutic index' and its clinical
implication for prescribing?
A. A high therapeutic index indicates a narrow margin between therapeutic and toxic doses.
B. A low therapeutic index requires routine therapeutic drug monitoring to avoid toxicity.
CORRECT
C. Therapeutic index is calculated as the median toxic dose divided by the median effective
dose.
D. Drugs with a low therapeutic index are safer because they have fewer side effects.
RATIONALE: A low therapeutic index means the toxic dose is close to the effective dose,
necessitating monitoring. Option A reverses the definition. Option C is incorrect; TI is
TD50/ED50. Option D is false; low TI drugs are less safe.
Page 4
5333 test 1 Exam (2026) UPDATE Verified Questions And Answers With 100% Correct Answers
graded A+ Guaranteed Success!!, with the strongest emphasis placed on Analyze pharmacokinetic
and pharmacodynamic principles to predict drug response and adverse effects in complex patient
scenarios, Apply current evidence-based guidelines to select, monitor, and adjust pharmacologic
therapy for common and high-risk conditions, Integrate pathophysiologic mechanisms with clinical
data to formulate safe and patient-centered prescriptive decisions. Every item follows the wording
style and level of reasoning you meet in the real paper, and each one is paired with a clear
rationale so the correct choice is never a guess. Work through the set at your own pace, mark the
questions that slow you down, then come back to them until the reasoning feels automatic.
Learners who revise this way walk into the exam room recognising the pattern behind the
questions instead of meeting them for the first time. Keep going - steady, honest practice is what
turns a difficult paper into a comfortable pass.
Q1 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
A patient with heart failure and reduced ejection fraction (HFrEF) is initiated on
sacubitril/valsartan. Which mechanism best explains why this agent must not be
co-administered with an ACE inhibitor within 36 hours?
A. Additive bradykinin accumulation from dual neprilysin and ACE inhibition increases
angioedema risk. CORRECT
B. Sacubitril inhibits ACE, leading to unopposed angiotensin II effects and hypertension.
C. Valsartan blocks AT1 receptors, causing reflex tachycardia that negates sacubitril's benefit.
D. Combined therapy reduces renal perfusion by inhibiting prostaglandin synthesis.
RATIONALE: Sacubitril inhibits neprilysin, which degrades bradykinin; concurrent ACE inhibition
also raises bradykinin, markedly increasing angioedema risk. Option B is false because sacubitril
does not inhibit ACE. Option C is incorrect because reflex tachycardia is not the primary concern
and valsartan does not negate sacubitril's benefit. Option D is unrelated; prostaglandin synthesis
is not the mechanism.
Page 2
,Q2 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
Which pathophysiologic alteration best explains the development of hyperkalemia
in a patient with metabolic acidosis and insulin deficiency?
A. Increased renal potassium excretion due to aldosterone excess
B. Extracellular shift of potassium via H+/K+ exchange and reduced cellular uptake CORRECT
C. Enhanced sodium-potassium ATPase activity driving potassium intracellularly
D. Decreased gastrointestinal potassium absorption
RATIONALE: In acidosis, hydrogen ions move into cells in exchange for potassium moving out;
insulin deficiency further impairs cellular potassium uptake, causing hyperkalemia. Option A is
wrong because aldosterone excess would lower potassium. Option C would lower serum
potassium. Option D does not cause hyperkalemia; reduced GI absorption would lower
potassium.
Q3 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
A patient on warfarin for atrial fibrillation is prescribed
trimethoprim-sulfamethoxazole for a urinary tract infection. Which
pharmacokinetic interaction is most likely to occur?
A. Induction of CYP2C9, decreasing INR and thromboembolic risk
B. Inhibition of CYP2C9, increasing INR and bleeding risk CORRECT
C. Increased renal clearance of warfarin, reducing its effect
D. Displacement from albumin without altering free drug concentration
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, the enzyme metabolizing
S-warfarin, leading to increased INR and bleeding risk. Option A is incorrect because induction
would decrease INR. Option C is wrong; renal clearance is not the primary mechanism. Option D
is incorrect because displacement alone does not usually cause a sustained increase in free drug
unless metabolism is also inhibited.
Page 3
, Q4 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
A patient with type 2 diabetes and chronic kidney disease (eGFR 32 mL/min/1.73
m²) is on metformin. Which action is most appropriate according to current FDA
labeling and clinical guidelines?
A. Continue metformin at current dose with routine monitoring.
B. Discontinue metformin and initiate an SGLT2 inhibitor. CORRECT
C. Reduce metformin dose by 50% and recheck eGFR in 3 months.
D. Switch to a sulfonylurea due to renal safety.
RATIONALE: Metformin is contraindicated when eGFR is below 30 mL/min/1.73 m² and should
not be initiated; at eGFR 32, many guidelines recommend discontinuation or dose reduction, but
an SGLT2 inhibitor is preferred for renal and cardiovascular protection. Option A is unsafe.
Option C is not aligned with current recommendations. Option D is less optimal because
sulfonylureas risk hypoglycemia in CKD.
Q5 ANALYZE PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT
DRUG RESPONSE AND ADVERSE EFFECTS IN COMPLEX PATIENT SCENARIOS
Which statement best describes the concept of 'therapeutic index' and its clinical
implication for prescribing?
A. A high therapeutic index indicates a narrow margin between therapeutic and toxic doses.
B. A low therapeutic index requires routine therapeutic drug monitoring to avoid toxicity.
CORRECT
C. Therapeutic index is calculated as the median toxic dose divided by the median effective
dose.
D. Drugs with a low therapeutic index are safer because they have fewer side effects.
RATIONALE: A low therapeutic index means the toxic dose is close to the effective dose,
necessitating monitoring. Option A reverses the definition. Option C is incorrect; TI is
TD50/ED50. Option D is false; low TI drugs are less safe.
Page 4
